- Infinity Pharmaceuticals (INFI) reports preclinical data that demonstrates the activity of IPI-145 (PI3K inhibitor) in models of DLBCL and T-ALL.
- INFI also says Phase 1 data in aNHL shows the treatment "led to a reduction in adenopathy" in three of eight DLBCL patients and two of three with Richter transformation. (PR)
- in other company news from ASH, INFI says updated Phase 1 data from an ongoing study in relapsed/refractory indolent iNHL shows IPI-145 is clinically active "with an overall response rate of 73%." There were 3 CRLs and 53% of patients "remained progression free for over one year." (PR)
- Finally, INFI says IPI-145 "was highly active in patients with relapsed/refractory CLL." Nodal response rate: 89%. OR rate: 48%. (PR)
Infinity Pharmaceuticals reports data from IPI-145 blood cancer studies
Dec 8 2013, 13:33 ET